RYBREVANT: A Breakthrough in Lung Cancer Treatment

1. RYBREVANT is a targeted therapy designed to treat advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations as a first-line treatment for adults.
2. Subcutaneous (SC) formulation outperforms intravenous (IV) version: The SC version of RYBREVANT significantly reduced the risk of death by 38% compared to the IV version in patients with EGFR ex19del or L858R mutations.
3. Improved convenience and tolerability: The SC version showed a fivefold reduction in infusion-related reactions and a better tolerability profile compared to the IV version.
4. Enhanced immune-mediated activity: The SC absorption via the lymphatic system potentially enhances immune-mediated activity, leading to better outcomes.
5. Multiple approvals and submissions: RYBREVANT has received approvals in the U.S. and Europe for various indications, including monotherapy and combination therapy for NSCLC with EGFR exon 20 insertion mutations.